Polyherbal Preparation Research Articles

Harnessing Phytochemicals to Regulate Catalytic Residues of Alpha-Amylase and Alpha-Glucosidase in Type 2 Diabetes.

Type 2 diabetes (T2D), also known as non-insulin-dependent diabetes mellitus, represents the prevailing manifestation of diabetes, encompassing a substantial majority of cases, ~90-95%. Plant-derived antidiabetic leads are being intensively explored due to their safety and effectiveness. The main objective of the present study is to evaluate the anti-diabetic potential of the traditional formulation Karisalai Karpam through in-vitro and in-silico investigations. The in-vitro and in-silico investigation of traditional polyherbal preparation Karisalai Karpam (KK) chooranam were performed to ascertain its inhibitory potential against α-amylase and α-glucosidase enzymes along with antioxidant (DPPH and ABTS) and phytochemical analysis. The results of enzyme inhibitory activity of KK witnessed highest activity against α-glucosidase enzyme with a percentage inhibition of 84.66 ± 2.50% (IC50,187.9 ± 5.79 μg/ml) followed by moderate level of α-amylase inhibition exhibited with 72.94 ± 3.66% (IC50, 241.6 ± 9.76 μg/ml). Additionally, the strongest antioxidant activity was observed in quenching DPPH• (IC50,154.8 ± 14.53 μg/ml) and ABTS+• radicals (IC50,148.6 ± 29.74 μg/ml). The outcome of the molecular docking studies indicated that among the 17 compounds analysed, the lead such as acalyphin, apigenin, humulene, and indirubin exhibited a prominent binding affinity over the residual binding site of α-glucosidase. It's important to note that the catalytic site of the enzyme α-amylase is primarily occupied by amyrin, apigenin, arjunolic acid, β-sitosterol, geraniol, and tricetin. In conclusion, the formulation KK demonstrates robust alpha-glucosidase and alpha-amylase inhibitory activity. It's also worth noting that the formulation exhibits noteworthy antioxidant properties, which could provide additional health benefits. The binding mode and energies of the identified phytochemicals against the target enzymes further support the formulation's antidiabetic potential.

Transcriptomics-based anti-tuberculous mechanism of traditional Chinese polyherbal preparation NiuBeiXiaoHe intermediates.

Integrated traditional Chinese medicine and biomedicine is an effective method to treat tuberculosis (TB). In our previous research, traditional Chinese medicine preparation NiuBeiXiaoHe (NBXH) achieved obvious anti-TB effects in animal experiments and clinical practice. However, the action mechanism of NBXH has not been elucidated. Peripheral blood mononuclear cells (PBMCs) were collected to extract mRNA and differentially expressed (DE) genes were obtained using gene microarray technology. Finally, GEO databases and RT-qPCR were used to verify the results of expression profile. After MTB infection, most upregulated DE genes in mice were immune-related genes, including cxcl9, camp, cfb, c4b, serpina3g, and ngp. Downregulated DE genes included lrrc74b, sult1d1, cxxc4, and grip2. After treatment with NBXH, especially high-dose NBXH, the abnormal gene expression was significantly corrected. Some DE genes have been confirmed in multiple GEO datasets or in pulmonary TB patients through RT-qPCR. MTB infection led to extensive changes in host gene expression and mainly caused the host's anti-TB immune responses. The treatment using high-dose NBXH partially repaired the abnormal gene expression, further enhanced the anti-TB immunity included autophagy and NK cell-mediated cytotoxicity, and had a certain inhibitory effect on overactivated immune responses.

Thin-layer chromatography image analysis with leave-1-out method and cross-sectional study for quality assessment of a polyherbal preparation ‘Phikud Navakot’

Thin-layer chromatography image analysis with leave-1-out method and cross-sectional study for quality assessment of a polyherbal preparation ‘Phikud Navakot’

Commercial Chinese polyherbal preparation: current status and future perspectives.

With the modernization of traditional Chinese medicine (TCM) industry, the investment in research and development of new commercial Chinese polyherbal preparations (CCPPs) is increasing, and the varieties of CCPPs are growing. CCPPs play an increasingly important role in the TCM industry. This study has comprehensively summarized and analyzed the current situation of CCPPs that has been on the market in China, and provided suggestions for the research and promotion of CCPPs. This study took the CCPPs approved for marketing in domestic drug database of the National Medical Products Administration (NMPA) as the research object, and combined with the publication of related randomized controlled trials (RCTs) of CCPPs in 2020-2022 and the sales of CCPPs in domestic chain pharmacies, statistical analysis was carried out on the drug name, pharmaceutical companies, dosage form, number of flavors, CBDs, ICD-11 classification of diseases treated, etc. Currently, 58,409 approvals for CCPPs have been issued in China, involving 9,986 varieties of CCPPs, 2,896 pharmaceutical companies and 39 dosage forms. The number of flavors of prescriptions of CCPPs varies from 1 to 90, among which Glycyrrhiza glabra L. [Fabaceae; Glycyrrhizae radix et rhizoma] and Angelica sinensis (Oliv.) Diels [Apiaceae; Angelicae sinensis radix] are the most widely used. The study found that the CCPPs with the most diverse variety is CCPPs for the treatment of respiratory diseases, some CCPPs can treat multiple system diseases. According to the survey, the sales of CCPPs for respiratory diseases in the chain pharmacies account for more than 1/3 of the total sales of the chain pharmacies, while the number of published randomized controlled trials (RCTs) on CCPPs for circulatory diseases was the largest. The approval process of CCPPs should be further standardized, and the transformation of TCM prescriptions into CCPPs should be promoted. In the approval process of CCPPs, it is suggested to strengthen the supervision of drug names to clarify the differences between the CCPPs of same name but different prescriptions. Improve the effectiveness and safety of CCPPs by improving the quality of CBDs. It is suggested to optimize the design of new drug research program of CCPPs to avoid waste of research resources.

Effects of the combination of red yeast rice-containing commercial Chinese polyherbal preparation with statins for dyslipidemia: a systematic review and meta-analysis.

Significant challenges are associated with the pharmacological management of dyslipidemia, an important risk factor for cardiovascular disease. Limited reliable evidence exists regarding the efficacy of red yeast rice (RYR)-containing commercial Chinese polyherbal preparation (CCPP), despite their widespread use in China. We aimed to investigate the efficacy of RYR-containing CCPPs combined with statins in treating dyslipidemia. Eight databases were searched for relevant randomized controlled trials (RCTs) from database inception date to November 2023. Outcome measures, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG), clinical efficacy, and adverse reactions, were assessed. The Cochrane Handbook for Systematic Reviews of Interventions was used for quality evaluation, and the meta-analysis was conducted using RevMan 5.3 and Stata 15.1. Thirty-three studies involving 4,098 participants were included. The combination of RYR-containing CCPP, such as Xuezhikang (XZK), Zhibitai (ZBTAI), or Zhibituo (ZBTUO) with statins had a significant effect on the increase in clinical efficacy [RR:1.16, 95%CI (1.13, 1.19), p < 0.00001]. In addition, they also improved blood lipid profile parameters by increasing HDL-C levels [MD:0.21, 95%CI(0.17, 0.25), p < 0.00001], and decreasing TC [MD: 0.60, 95%CI(-0.76, -0.45), p < 0.00001], TG [MD: 0.33, 95%CI(-0.39, -0.26), p < 0.00001] and LDL-C levels [MD: 0.45, 95%CI(-0.54, -0.36), p < 0.00001]. No significant adverse reactions was observed in the RYR-containing CCPPs. Notably, ZBTAI and XZK significantly reduced the incidence of gastrointestinal disturbances and muscular adverse reactions. However, subgroup analyses suggested that the type of CCPPs, dose, and treatment duration might affect the efficacy of RYR-containing CCPPs. RYR-containing CCPPs combined with statins appears to improve lipid profiles and clinical efficacy in patients with dyslipidemia. However, due to the poor quality of the included studies, and some studied showing negative findings was unpublished. The results should be interpreted with caution until further confirmation by well-designed RCTs. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=487402, identifier CRD42023487402.

Sub-chronic Hepatotoxicity Assessment of Ghana Cleanser® in Exposed Wistar Rats

This study evaluated the toxicity of a polyherbal Formulation (Ghana Cleanser®) on liver function markers of exposed albino rats. Thirty (30) male and female rats of the Wistar strain were randomly allotted into six (6) groups with n=5. 10.0 mL/kg distilled water was given to control groups 1 and 4. Polyherbal formulation doses of 374.0 mg/kg and 187.0 mg/kg were administered to groups 2-3 and 5-6, respectively. A modified Lorke's approach was used to compute acute toxicity. Animals were euthanized after 60 days under diethyl ether. Blood was collected for biochemical analyses through cardiac puncture. The liver was excised from each animal and was fixed in 10% buffered formaldehyde and prepared for histological assessment. LD50 of the polyherbal preparation was calculated as 3740 mg/kg (oral). The results indicated an appreciable increase (p&lt;0.05) in ALT activity at 374.0 mg/kg in female rats; while there was no increase recorded at 187.0mg/kg in male rats. A significant increase in ALT activity was recorded at 374 mg/kg in male rats as well and increased AST activities were recorded at 187mg/kg in female rats. In the treated animals of both sexes, ALP activities were significantly elevated. Histopathology assessment of the hepatocytes showed no significant damage at 187 mg/kg in rats of both sexes when compared with their respective controls while some degrees of pathologies such as hepatocyte inflammation, hyperplasia, and congestion were recorded at 374 mg/kg in rats of both sexes. Results suggest caution on the long-term use of the polyherbal mixture due to its hepatotoxic potential.

Evaluation of Hepatoprotective and Nephroprotective Impact of Phytomedicine using Experimental Animal Models

Human beings have been using plants as medicines for centuries. The development of traditional medicinal systems utilizing plants as a form of medicine may be traced back only as far as historical documentation of their similarity. Immunosuppression and bone resorption is a major drawback in conventional chemotherapy. Modern medicines contain plant-derived components that are the source of immunomodulators. Withania somnifera and Cnidium monnieri are the plants which have been used for immunomodulatory and anti-osteoporotic activities. Medicinal plant samples were obtained from diverse parts of Pakistan. Following extraction, phytochemical analysis and antimicrobial potential were investigated, and the hepatoprotective effect was evaluated. An in vivo study was conducted on experimental animals by administering ethnomedicinal plant extracts in comparison to some allopathic drugs. Various blood samples were collected to analyze calcium level, vitamin-D, thyroid-stimulating hormone (TSH), parathyroid hormone (PTH), follicle stimulating hormone (FSH), and Testosterone for antiosteoporosis activity. The possible outcomes were positive and hepatoprotective as well as antimicrobial effect was present in Polyherbal preparation (PHP). During trails on Albino rats, the improvement in their body weight was recorded. PHP administration of plant extracts enhanced the parameters of blood and neutralized the effect of CCl4 intoxication. The proper administration of plant extracts showed a positive effect on hormones, particularly progesterone, testosterone, and oestradiol. In the future, these selected medicinal plants and their PHP might be preferred for the separation of lead bioactive compounds to overcome the extremely alleviating issues associated with infertility.

Commercial Chinese polyherbal preparation Zao Ren An Shen prescription for primary insomnia: a systematic review with meta-analysis and trial sequential analysis.

Background: Natural products are widely used for primary insomnia (PI). This systematic review with trial sequential analysis (TSA) aimed to summarize evidence pertaining to the effectiveness and safety of Zao Ren An Shen (ZRAS) prescription, a commercial Chinese polyherbal preparation, for treating PI. Methods: Controlled clinical trials appraising ZRAS compared to controls or as an add-on treatment were systematically searched across seven databases until January 2024. Cochrane ROB 2.0 and ROBINS-I tools were adopted to determine risk of bias. Quality of evidence was assessed using the GRADE framework. Results: We analyzed 22 studies, involving 2,142 participants. The effect of ZRAS in reducing Pittsburgh Sleep Quality Index scores was found to be comparable to benzodiazepines [MD = 0.39, 95%CI (-0.12, 0.91), p = 0.13] and superior to Z-drugs [MD = -1.31, 95%CI (-2.37, -0.24), p = 0.02]. The addition of ZRAS to hypnotics more significantly reduced polysomnographically-recorded sleep onset latency [MD = -4.44min, 95%CI (-7.98, -0.91), p = 0.01] and number of awakenings [MD = -0.89times, 95%CI (-1.67, -0.10), p = 0.03], and increased total sleep time [MD = 40.72min, 95%CI (25.14, 56.30), p < 0.01], with fewer adverse events than hypnotics alone. TSA validated the robustness of these quantitative synthesis results. However, the quality of evidence ranged from very low to low. The limited data available for follow-up did not support meta-synthesis. Conclusion: While ZRAS prescription shows promising effectiveness in treating PI, the overall quality of evidence is limited. Rigorously-designed randomized control trials are warranted to confirm the short-term efficacy of ZRAS and explore its medium-to-long-term efficacy. Systematic Review Registration: (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=471497), identifier (CRD42023471497).

Fermented Polyherbal Formulation Ameliorates the Severity of Acute Multiple Antibiotics-Resistant Pseudomonas aeruginosa-Infected Burn Wound in a Rat Burn Model.

Pseudomonas aeruginosa, a Gram-negative opportunistic bacterium, has emerged as a cause of life-threatening infections in burn wounds. Current therapeutic approaches through wound dressings and systemic medicines are far from satisfactory; resistance to more than two antibiotics shown by pathogens contributes to failures of therapy causing mortality. This animal study was conducted to check the efficacy of one Ayurveda-based fermented polyherbal preparation (AP 01) against multiple antibiotics-resistant (MAR) P. aeruginosa HW01-infected rat burn wounds. AP-01 was applied on artificially infected burn wound on a rat model infected with MAR P. aeruginosa to register the healing effects in terms of reduction in residual wound area percentage, the presence of C-reactive protein in blood, and the presence of viable bacteria colony. Topical application with conventional antibiotics served as a positive control. The polyherbal preparation had reduced the infected residual burn wound area at 40.63% ± 0.69 from the initial burn wound area within two weeks after a single intervention, whereas residual burn wound area remained much higher in the case of animals left untreated and in the case of the animals treated with control drug. Restoration to the normalcy of serum C-reactive protein level was also achieved earlier in the case of polyherbal AP-01-treated groups than in other groups. Fermented formulations using components of AP-01 singly or in different combinations had never been tested earlier for topical application in infected burn wound. The formulation of AP-01 was found superior in terms of the rate of healing and control of infection by MAR P. aeruginosa strains in burn wounds in rat models.

Attenuation of Bleomycin-induced Toxicity on Selected Respiratory Function Metrics in Rabbits by a Polyherbal Preparation

Attenuation of Bleomycin-induced Toxicity on Selected Respiratory Function Metrics in Rabbits by a Polyherbal Preparation

A REVIEW ON TRIKATU CHURNA

Ayurveda has an ancient heritage of traditional herbs in which Trikatu is very precious. Trikatu is a poly herbal preparation. It consists of three crude drugs namely Maricha (Piper nigrum Linn). Pippali (Piper longum Linn) and Shunthi (Zingiber officinalis Rosc) in the ratio of (1:1:1; ww). Trikatu also called as Katutrikam, Tryusnam, Vyosa. Trikatu is used as solo drug rarely, but it is an essential ingredient of numerous formulations and prescriptions of Ayurvedic medicine. Trikatu churna is considered as one of the best drugs to treat the condition of Ama (improperly digested absorbed and improperly metabolised food particles including free radicles). Trikatu is regarded as the drug of choice in cases of Agnimandya (poor digestion due to faulty digestive process). In Brihattrayi, it is recommended for various diseases due to Agni (digestive fire) vitiation such as Grahaniroga (Malabsorption syndrome), Udara roga (major diseases of abdomen surgical and medical like hepatomegaly, splenomegaly and ascites), Arsharoga (piles) etc. Its contents are dipana and pacana in their action. By virtue of these properties the drug becomes effective in managing ama. The objective of this article is to highlight classification, synonyms, pharmacological actions as described in various diseases, and different formulations of Trikatu in ancient Ayurvedic.

Ifanosine: Olea europaea L. and Hyphaene thebaica L. combination, from traditional utilization to rational formulation: Preclinical and clinical efficacy on hypertensives patients

Ethnopharmacological relevanceOlea europaea L. and Hyphaene thebaica L. are commonly employed by traditional healers in Africa for treating and preventing hypertension, either individually or in a polyherbal preparation (Ifanosine). Aim of the studyThe primary aim was to assess the antihypertensive effects of Olea europaea L. leaves aqueous extract (OEL), Hyphaene thebaica L. mesocarp extract (HT), and the Ifanosine on isolated rat aorta rings. The secondary objective was to evaluate the clinical benefits of a new oral formulation of Ifanosine. Materials and methodsIn vitro studies using an isometric transducer examined the antihypertensive effects of HT, OEL, and Ifanosine on rat aorta. Ussing chambers technic were employed to measure mucosal to serosal fluxes and total transepithelial electrical conductance (Gt) to assess the intestinal bioavailability of HT, OEL, and Ifanosine. HPLC was utilized to determine the phytochemical composition of OEL and HT extracts. Subchronic toxicity investigations involved two groups of rats, treated with either water (control) or Ifanosine at 5 g/kg for 28 days. Clinical benefits of the new Ifanosine formulation were evaluated in an observational study with 32 hypertensive patients receiving a fixed oral dose of 3.5 mg three times a day for 30 days. ResultsAqueous extracts induced dose-dependent relaxation of rat aorta rings, with HT and OEL having higher IC50 values than Ifanosine (IC50 = 44.76 ± 1.35 ng/mL, 58.67 ± 1.02 ng/mL, and 29.46 ± 0.26 ng/mL, respectively). The pA2 values of OEL and HT were 1 and 0.6, respectively, while Ifanosine was 0.06. Intestinal bioavailability studies revealed better Prazosin bioavailability than plant extracts. Toxicological studies demonstrated the safety of Ifanosine, supported by histological examinations and biochemical parameters in rat blood. Biochemical analyses indicated flavonoids and phenolic acids as dominant active constituents. Clinical benefits in humans included reduced SBP, DBP, LDL-c, VLDL-c, and TAG, and increased HDL-c without overt adverse effects. ConclusionThis study validates the traditional use of OEL and HT for hypertension and advocates for alternative and combinatorial polyphytotherapy (ACP) to enhance traditional remedies.

Fast dissolving tablets: Opportunity in herbal drug delivery system

The polyherbal preparation's pharmacological and phytochemical properties have been used all over the world. Single or multiple herbs (polyherbal) are utilized for treatment in Ayurveda. The Sarangdhar Samhita, a work of Ayurvedic literature, emphasized the idea of polyherbalism as a means of enhancing therapeutic efficacy. Individual plants' active phytochemical components are insufficient to produce the desired therapeutic effects. The medicinal effects and toxicity are improved when different herbs are combined in a specific ratio. Comforts of drug administration and patient compliance are given significant weight when designing dose forms. New and developing technology can be used to produce durable, adaptable tablets with exceptional flavor masking and controlled release. Orally disintegrating tablets (ODTs) are solid dosage forms that disintegrate in the mouth in less than 60 s, and are thus swallowed without the need for water. Rapid disintegration of tablet cause quick dissolution thus rapid onset of action. Polyherbal Fast dissolving Tablets disintegrates in mouth quickly and produces fast onset of action without use of water makes it suitable for special population like pediatrics, geriatrics, psychotic, dysphasic, bedridden patient and frequent traveller patient. The current review article explains the features of active ingredients and excipient used in the formulation of ODTs, discusses multiple ODT formulation and preparation techniques with their merits and demerits, and also, offers remedies for problems associated with ODTs. Moreover, quality control steps and required considerations are presented.

Genetic memory activation of the skin by polyherbal preparation – A new hope for pigmentary disorders of the skin

ABSTRACT The present article describe the photosensitizing effect of Psoralea corylifolia extract specific to accelerate melanogenesis in skin by eliciting the release of certain pro-inflammatory mediators by fibroblast and keratinocytes; responsible for melanogenesis. The process of acceleration of pigmentogenesis which we refer as ‘activation of genetic memory of the skin’. The findings of the cell culture assay using B16F10, fibroblast and keratinocyte cell line studies have been described in the article. Further, the importance of UV irradiation post Psoralea corylifolia extract treatment in releasing the pro-inflammatory mediators by fibroblast and keratinocyte also has been described. The study findings clearly indicate the inclusion of herbal preparations in the treatment of vitiligo which may offer some treatment value, however further confirmation is required.

Safety evaluation of a proprietary ayruveda-based polyherbal preparation (arthralgex) used for arthritis.

Arthralgex is a proprietary polyherbal preparation used in clinics to treat rheumatoid arthritis for decades. Its safety evaluation has not been reported. The study is aimed at evaluating the safety of arthralgex using Wistar rats, as per OECD guidelines. According to OECD 407, rats of either gender were separated into six groups (n= 6 each). The dose of arthralgex was decided based on an acute toxicity study. Under the treatment group, separate set of rats received arthralgex in three dose levels like - low, medium, and high (200, 400 & 800 mg/kg/day; p.o for 28 days). Satellite groups received high dose (800 mg/kg/day, p.o for 28 days), and control group received equal volume of vehicle. On day 28, blood samples were collected to estimate hematology and biochemistry parameters. Subsequently, rats were euthanized to collect organs for weighing and histopathology. Satellite groups were maintained for an additional 14 days post-treatment to assess toxicity reversibility and euthanized on day 43. Arthralgex did not show any signs of toxicity or major change in body weight in the acute toxicity study. Arthralgex has no significant adverse effect on general health status as confirmed by body weight, feed intake, hematology, biochemistry, urine analysis, internal organs, relative organ weight, and histopathological evaluation after 28 day treatment. Arthralgex could be considered safe for short-term treatment. Present findings may help researchers in dose fixing for sub-chronic and chronic toxicity studies, which is essential for safety evaluation for long-term use.

Diabetic neuropathy protective action of polyherbal preparation

Diabetic neuropathy protective action of polyherbal preparation

Efficacy and safety of Link Natural Sudarshana, an Ayurvedic herbal preparation in COVID-19 patients: A phase II multicenter double-blind randomized placebo-controlled trial

Ethnopharmacological relevanceIn vitro and in vivo studies have shown anti-viral and immunomodulatory actions in components of many traditional medicines. Various constituents of traditional medicines have been found to be effective against coronavirus disease (COVID-19) in several clinical trials and in-silico studies. Sudarshana cúrna, a polyherbal Ayurvedic medicine, has been used over thousands of years for a variety of infectious fevers. Aims of the studyThis study aimed to evaluate the efficacy and safety of Link Natural Sudarshana (LNS) tablets, in patients with COVID 19 disease. LNS is a polyherbal preparation comprising 49 medicinal plants included in the Sudarshana cúrna. Materials and methodsA randomized parallel-group double-blind placebo-controlled multi-center phase II clinical trial was conducted in patients with mild to moderate COVID-19 disease. They were randomly allocated to intervention and control groups. The intervention group received LNS tablets whereas the control group received placebo tablets for 10 days or until the patient was discharged from the hospital. All patients received standard symptomatic treatment. The primary outcome, a reduction in mean log viral load was assessed at day 5 of treatment. The secondary outcomes, clinical progression and safety, were assessed by, monitoring changes in symptoms daily on a Likert scale ranging from 1 to 4 and laboratory tests respectively. ResultsA total of 171 patients (treatment group 83, control group 88) completed the trial. There were no significant differences between the baseline status of the two groups except that body mass index was significantly higher in the placebo group. The mean log viral load reduction at day 5 was higher in the treatment group (2.20 ± 1.67) compared to the placebo group (1.93 ± 1.80), with a mean difference of −0.278. This difference was not statistically significant at the 5% significant level. Reduction of mean cumulative symptom score, which included 16 symptoms graded according to severity, was higher in the treatment group compared to the placebo group. This difference was not statistically significant. None of the study participants developed hypoxia. Among the 7 lymphopenia patients in the placebo group, 3 continued to have lymphopenia at day 10, whereas 9 lymphopenia patients in the treatment group, reverted to normal counts. C reactive proteins (CRP) showed a greater reduction in the treatment group. None reported adverse effects. No significant changes occurred in hematological and biochemical parameters that assessed safety. ConclusionsLNS is safe to use in COVID-19 patients and accelerated the decline in viral load, relieved symptoms, reduced CRP levels and reversed lymphopenia earlier, when compared to the placebo.

Clinical Effect of Poly Herbal Unani Formulation on Dyslipidemia- A Randomized Trial

Background: In adults aged 30-70 with primary and moderate hyperlipidemia, the present study took place to investigate the therapeutic benefits of a polyherbal unani preparation called Garlitab. Methods: It was a prospective open label, herbal coded test drug-controlled, randomized trial. Out of total screened patients we were enrolled 212 hyperlipidemic patients of 30–70 years in the study fulfilling the inclusion criteria, we were recruited them from OPD of a hospital in Munshiganj and different Unani clinics of Dhaka, Bangladesh after obtaining written informed consent from the patients. Selected individuals were allocated into two groups at random. Group1 Received 500 mg Garlitab tablets twice daily and Group 2 received tablet atorvastatin calcium 10 mg 2 times daily. Height, weight, and blood pressure were recorded along with blood samples. The random distributions were carried out by a research assistant utilizing a random numbers table. Blood samples were taken at the beginning of the trial, 1.5 months later, and 3 months following the intervention. Results: Results for the test medication revealed a substantial drop in cholesterol levels between baseline and the data collected after three months and in case of male it was from 241.72±38.11 to 218.24±34.06 mg/dL for total cholesterol, from 198.27±30.57 to 173.54±29.34 mg/dL for LDL and from 280.78±85.81 to 207.07±51.40 mg/dL for triglyceride. HDL increases from 33.05±3.21 to 34.69±3.13 mg/dL in male patients. The control drug atorvastatin calcium also showed a significant decrease in lipids between baseline and after 3 months data and in case of male it was from 241.92±31.54 to 174.90±22.87 mg/dL for total cholesterol, from 196.20±30.91 to 130.30±24.29 mg/dL for LDL and from 279.48±115.35 to 141.27±59.55 mg/dL for triglyceride. It increases HDL from 32.00±2.25 to 34.03±2.19 mg/dL in male patients. Between the baseline and the 3-month data, the test medicine for females significantly reduced total cholesterol, LDL, and triglycerides and it was from 244.64±52.18 to 220.12±45.07 mg/dL, from 200.32±30.57 to 173.54±29.34 mg/dL and from 272.32±99.69 to 195.25±60.68 mg/dL respectively. HDL increases from 33.77±3.36 to 35.03±3.23 mg/dL. Between the baseline and the 3-month data, the control medication for females significantly reduced total cholesterol, LDL, and triglycerides and it was from 247.74±37.95 to 175.26±29.54 mg/dL, from 197.65±27.89 to 130.91±22.04 mg/dL and from 271.57±94.52 to 142.00±50.88 mg/dL respectively. It increases HDL from 32.22±2.32 to 33.46±2.94 mg/dL. Conclusions: According to the results of the study, the polyherbal formulation Garlitab can lower cholesterol levels. It may be a useful medication for treating primary hyperlipidemia.

In vitro anti-cancer activity of a polyherbal preparation, VEDICINALS®9, against A549 human lung adenocarcinoma cells

PurposeNon-small cell lung cancer (NSCLC) is among the leading causes of morbidity and mortality worldwide. Despite the availability of several treatment options, the five-year survival rate of NSCLC is extremely low (<20%). This underlines the necessity of more effective therapeutic alternatives. In this context, plant-derived extracts and bioactive molecules extracted from plants, known collectively as phytoceuticals, represent an extremely variegated source of bioactive compounds with potent anticancer potential. In the present study, we tested the in vitro anticancer activity of a polyherbal preparation, VEDICINALS®9, containing nine different bioactive principles extracted by medicinal plants. MethodsThe anticancer activity of VEDICINALS®9 was investigated by measuring its impact on A549 human NSCLC cell proliferation (MTT assay and trypan blue staining), migration (wound healing assay and transwell chamber assay) and by measuring the impact on the expression of cancer-related proteins (Human XL Oncology Protein Array). ResultsWe show that VEDICINALS®9 at a concentration of 0.2% v/v has potent anticancer effect, significantly inhibiting A549 cell proliferation and migration. Mechanistically, this was achieved by downregulating the expression of proteins involved in cancer cell proliferation (Axl, FGF basic, enolase 2, progranulin, survivin) and migration (Dkk-1, cathepsins B and D, BCL-x, amphiregulin, CapG, u-plasminogen activator). Furthermore, treatment with VEDICINALS®9 resulted in increased expression of the oncosuppressor protein p53 and of the angiogenesis inhibitor endostatin. ConclusionsTaken together, our results provide proof of principle of the potent anticancer activity of the polyherbal preparation VEDICINALS®9, highlighting its enormous potential as an alternative or adjuvant therapy for lung cancer.

A REVIEW OF BILWADI AGADA AND APAMARGA MOOLA ON VRISHCHIK DAMSHA CHIKITSA, AN AYURVEDIC MANAGEMENT FOR SCORPION BITE

A sort of poison generated by an animal that is actively administered through a wound by way of a bite, sting, or other similar action is known as venom or zootoxin.[1][2][3] The process of envenomation involves the delivery of the poison through a specially evolved venom mechanism, such as fangs or a stinger. National public health data show that there are 1.5 million scorpion envenoming’s recorded worldwide each year, resulting in 2000–3000 fatalities. [4,5]. Scorpions (also known as Vrischika) are a type of Keeta (insect) because of the intensity of their poisoning and illness symptoms. Vrischika Visha has received special attention from Ayurveda acharyas and is referred to as a singular entity in the classics. The present work examines the therapeutic effects of Apamarg moola and Bilwadi agad, two commonly utilised medicinal herbs by traditional healers in the treatment of Vrishchik damsha (scorpions bite).A polyherbal ayurvedic preparation is called Bilwadi agada or gutika. In acute toxicopathological situations, it is a viable medication option.